WHAT'S KNOWN ON THIS SUBJECT: Childhood attention-deficit/ hyperactivity disorder has been associated with both childhood and adult obesity, whereas treatment with stimulants has been associated with delayed child growth. No longitudinal studies with details about dates of diagnosis, treatment, and duration of stimulant use have been published.
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common pediatric psychiatric disorders, with a prevalence in the United States approaching 9%. 1 As a likely consequence of this, stimulants, the most common therapy for ADHD, 2 are the second most commonly prescribed medications among children. 3 National data reveal that the prevalence of stimulant use has increased rapidly over the past 30 years. From 2007 to 2010, 4 .2% of children younger than 18 years had been prescribed stimulants within the past 30 days; this represented more than a fivefold increase in such use since 1988 to 1994. 3 There is substantial evidence that stimulant use is associated with growth deficits and some evidence of growth delays in ADHD. 4 However, increasingly, and paradoxically, concerns have been raised about a possible link between ADHD and obesity. Cross-sectional studies in children have reported an association between ADHD and obesity, [5] [6] [7] and childhood ADHD may be a risk factor for adult obesity. 2, 8, 9 The risk of obesity associated with ADHD may be reduced or eliminated among children who have received stimulants as treatment for ADHD. 6, 7, 10 However, the independent contributions of ADHD and the medications used to treat it have not been fully elucidated.
ADHD and stimulant use are promising avenues of research regarding the childhood obesity epidemic. In seeking explanations for the rapid increase in obesity rates over the past several decades, it is important to evaluate the role of risk factors that have also increased in prevalence within a similar time frame. ADHD and stimulant use meet this criterion and, given the limitations of previous studies that showed an association between ADHD and obesity, now merit a careful evaluation of their relative and independent contributions to BMI trajectories in children.
We used longitudinal electronic health record(EHR)datafromalarge,integrated health system to examine these relations for the first time.
METHODS

Study Population and Design
Data were obtained from children and adolescents (hereafter referred to as just children) with a primary care provider in the Geisinger Health System. These children represent the general population in the region. 11, 12 The study area included 37 counties in central and northeastern Pennsylvania and consisted of 1288 communities (defined as townships, boroughs, or census tracts in cities 11, 13, 14 ) . Only children whose home address could be geocoded to the street level were included in the analysis. The study was approved by institutional review boards at Geisinger Health System and Johns Hopkins Bloomberg School of Public Health.
Data Collection
We collected data on 257 729 children who were 2 to 18 years of age between January 2001 and February 2012. Of these, 206 395 had at least 1 height and weight measured in the clinical setting, after deleting biologically implausible values. A total of 173 048 children were successfully geocoded as previously reported 13, 14 and 163 820 were included in the analysis after exclusion of 2-year-olds because of difficulties in measuring height at this age. Data were obtained on sociodemographics, encounters, vital signs, laboratory tests, procedures, and medications. All orders and encounters were accompanied by International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic codes.
Variable Creation
Diagnosis of ADHD was based on ICD-9-CM codes 314.0 to 314.9 for outpatient encounters or medication orders. Stimulant use was based on physician orders for medications that occurred before the date of the last BMI measurement for each child. Relevant medications were identified by searching by name, class, and subclass codes. Duration of stimulant use was based on the dates of physician orders. Because most of the agents of interest are Schedule II Controlled Substances, physician orders must be written monthly. Each monthly order was assumed to cover all days in the month; multiple orders for the same drug from the same encounter were allocated to subsequent months. Comorbidities (ICD-9-CM code), includingasthma(493.x),diabetes(250.x), psychoses (290.x-299.x), depression (311), adjustment reaction and disorders (309.x), and anxiety (300.x), were considered present if there were 3 or more outpatient encounters or medication orders with the code. Medical assistance for health insurance was used as a surrogate for low family socioeconomic status.
Data Analysis
In longitudinal studies of childhood growth, there are several options for analysis, including untransformed BMI, BMI percentiles, or BMI z scores. 15 We modeled untransformed BMI values, because when modeling trajectories of change, this measure, as opposed to BMI z scores (which are age-adjusted, cross-sectional deviations from national norms), yields estimates that are more interpretable, precise, and sensitive to factors that alter change. 16 18, 19 Random effects included subject-specific intercepts and coefficients for age and age 2 to accommodate serial correlations and allow trajectories to vary across children. Random effects were allowed to covary via an unstructured covariance matrix, and fitting was accomplished by restricted maximum likelihood estimation. Because we observed inequality of the individual-level error variances by age, we used a group effect for age groups of 3 to 5, 5 to 8, and .8 years that allowed for heterogeneity in residual variances across groups. To model differences in BMI trajectories by demographic characteristics, models included cross-products of gender and medical assistance with all 3 age terms as fixed effects, and of race/ ethnicity with age and age ADHD diagnosis (ever versus never), age at first stimulant use (quartiles), and duration of stimulant use (quartiles [1-2, 3-6, 7-19, and 20-120 months] and also as a single ordinal variable [0-4] to assess the statistical significance of trends) were then added to the model, alone and in combination as main effects and with cross-products with the 3 age terms. Models were evaluated for goodness of fit, normality of residuals, and homoscedasticity; fit was also evaluated by comparing regression lines to lowess lines on added variable plots. To evaluate robustness of findings to assumptions of normality and homoscedasticity, models were repeated by using ln-transformed BMI and also a Huber-White estimator. 20 As there were no substantive differences, only the results of the primary models are presented.
RESULTS
Description of Study Population
The 163 820 children included approximately equal numbers of boys and girls, with a mean age at first BMI of almost 9 years, and 91% were white (Table 1 ). There were 1 to 13 BMI observations per subject with a total of 524 862 observations in the analysis. On average, children had just over 3 yearly BMI measurements, with an average duration between first and last measurements of 2.9 years. The mean (SD, range) duration from first contact with the health care system to the last (before age 19) was 4.88 (3.47, 0-11.51) years. Geocoded and nongeocodable children were not notably different, but children with and without ADHD had several differences (Table 1) . Thirty percent of children resided in boroughs (generally walkable small towns), 15% in census tracts in cities, and 55% in townships (include rural and suburban areas).
A total of 13 789 (8.4%) children had encounter diagnoses for ADHD (24.1% with only 1 diagnosis and 58.6% with $4); 11 080 (6.8%) had an order for stimulants; and 15 473 (9.5%) had either a stimulant order or an ADHD diagnosis. Among the children with only 1 ADHD diagnosis, 71.4% were never treated for ADHD. There were 201 854 orders for medications used in the analysis, including 105 504 for methylphenidate, 68 323 for dextroamphetamine/amphetamine, 12 380 for atomoxetine, 5297 for dexmethylphenidate, and the remainder mainly for dextroamphetamine or lisdexamfetamine dimesylate. The mean (median) stimulant duration was 426.3 (182.6) days. The median age at first stimulant order was 8.5 years. Children who had ever had a stimulant order were more likely to have received medical assistance, 54% compared with 32% for children without stimulant orders (P , .0001).
Average BMI Growth Trajectories
The average trajectory of BMI increase with age ("BMI growth") was curvilinear (Fig 1, by race/ethnicity). On average, girls had higher BMIs than boys at all ages (all age cross-products P , .0001). Although the average BMI growth trajectory did not differ in Hispanic children (compared with white children, P . .10), there was evidence that the trajectory did differ in African American children (cross-product for age P , .0001, for age 2 P = .07), with apparent divergence by age 5 years and widening as children got older. Children who had ever received medical assistance had higher BMIs at all ages compared with children who had not, with apparent divergence of the growth trajectories after age 8 years (all cross-product P , .0001).
BMI Trajectories by ADHD Diagnosis and Stimulant Use Categories
We compared the BMI trajectories of children who never received an ADHD diagnosis and never had a physician order for stimulants (referred to as "controls") with 3 groups: (1) those with a diagnosis of ADHD but without physician orders for stimulants, (2) those with orders for stimulants but without an ADHD diagnosis, and (3) those with both stimulant orders and ADHD diagnoses (Table 2 and Fig 2) .
Compared with controls, those in group 3 had slower rates of BMI growth in early childhood but more rapid rates during adolescence (P values for main effect and 3 crossproducts with age , 0.0001), with BMIs eventually exceeding those in controls. In contrast, those with a diagnosis of ADHD and without any stimulant orders (group 1) had more rapid BMI growth after age 10 years compared with controls (age crossproduct P , .0001). Children in group 2 had an average BMI trajectory that was intermediate between groups 1 and 3 but lower than controls.
BMI Trajectories by Age at First Stimulant Use and Duration
Younger age at first stimulant order was associated with slower BMI growth in early childhood, but the earlier stimulants were ordered, the earlier and stronger that BMI growth "rebounded" and eventually exceeded values in controls (Table 3 and Fig 3) . Examination of diagnostic plots suggested that data were sparse at age 17 and 18 years for children in the earliest age at first stimulant order group and that the high BMIs at these ages predicted by the model were somewhat overestimated.
Longer stimulant use duration evidenced consistent and strong impacts on BMI trajectories (Table 4 and Fig 4) . There was a trend toward lower average BMIs (at the mean age) across the 4 duration quartile groups (b coefficients across quartiles = -0.38, -0.50, -0.64, and -1.21, respectively, Table 4 ). This trend continued within the quartile of the longest duration of use. In addition, longer duration of stimulant use was associated with slower BMI growth at younger ages, but with more rapid acceleration of BMI growth at older ages (Fig 4) . To evaluate trends further, duration of stimulant use was re-parameterized by replacing the 4 groups with a single variable coded 0 to 4 (0 for controls and 1-4 for the 4 quartiles of duration) along with crossproducts with the 3 age terms. This analysis demonstrated that, with increasing duration of stimulant use, there was a consistent dose-response relation in terms of lower average BMIs (at the median age), slower early BMI growth, and increasing rates of BMI growth with later ages. After inclusion of comorbidities in the models, no substantive changes in these associations were observed.
Several sensitivity analyses were performed. To further explore BMI trajectories by age at first stimulant order and stimulant use duration, we divided each of these variables into tertiles and modeled trajectories in the 9 resulting groups. There was a mean (SD) of 1231.1 (335.8) children in each of the 9 groups.
The results suggested there were independent influences of age at first stimulant order and duration of stimulant use, with trends across tertiles for both variables. When regression models were repeated with nonstimulant ADHD medications removed, associations with age at first ADHD medication use and duration of use strengthened, and BMI trajectories in children treated only with nonstimulants were similar to those in untreated ADHD. When children treated with ADHD medications and other psychotropic medications were separately categorized (51.4% of children ever treated with ADHD medications were also ever treated with another psychotropic), associations with ADHD medications strengthened, as other psychotropic medication use was generally associated with accelerated BMI growth.
DISCUSSION
This is the first study to use longitudinal data from an EHR in a large population of children ages 3 to 18 years to examine the impact of ADHD diagnosis and treatment on BMI trajectories. We have made several observations that dramatically strengthen the evidence base regarding ADHD, stimulant use, childhood BMI trajectories, and obesity risk. The data suggest that children with unmedicated ADHD have faster rates of BMI growth after approximately age 10 years compared with controls with neither a history of ADHD nor stimulant use; children with ADHD treated with stimulants have reduced rates of BMI growth in early to mid-childhood but experience a "BMI rebound" in late childhood, after which BMI growth accelerates, leading to BMIs in late adolescence that are higher than those in controls. The findings are consistent with and may partially explain observed associations of childhood ADHD with adult obesity. 2, 8, 9 The associations of stimulants with BMI growth trajectories were robust to the metric used, with evidence of dose-response relations for both age at first stimulant order and stimulant use duration, and after adjustment for many relevant , race/ethnicity (separate terms for black, Hispanic, and other), race/ethnicity*age, race/ethnicity*age 2 , medical assistance, medical assistance*age, medical assistance*age 2 , medical assistance*age 3 , and community type (borough, census tract). b Diag-NoMeds indicates children who only had encounters with ADHD diagnoses without a record of stimulants for treatment; Meds-NoDiag indicates children who only had orders for stimulants without a record of ADHD diagnosis; Diag +meds indicates children who had both encounters of diagnoses for ADHD as well as orders for stimulants. For each group, BMI trajectories were modeled with linear, quadratic, and cubic terms for age. potential confounding variables. Findings strengthened after accounting for ADHD medications that were not stimulants, and for the common use of other psychotropic medications in children with ADHD, as these were associated with accelerated weight gain. The study overcomes many of the limitations of previous research, including those of cross-sectional designs, selfreported height and weight, lack of consideration of the independent roles of diagnoses and medication use, lack of consideration of duration of medication use, and incomplete consideration of other obesity risk factors.
Normative growth patterns for children demonstrate accelerated growth starting at age 5 years, with resultant steady increases in BMI until peak growth rate occurs at ∼13 to 14 years. 21 Factors that lead to early acceleration of BMI growth are generally recognized as obesogenic. 21, 22 With stimulant use, child growth deficits in height and weight have been observed; however, growth deficits show attenuation over time. Children "catch-up" to their prestimulant growth pattern within 2 to 3 years whether stimulant use continues or not. 4 Slower BMI growth seems to be most pronounced when stimulants are started earlier and for children who are taller or heavier when stimulant therapy is initiated. 4, 23, 24 Suggested mechanisms for stimulantinfluenced growth deficits may provide insight into observed BMI rebound by late childhood. Stimulants may function in multiple ways to alter usual growth. At the simplest level, their anorexic effects may reduce energy consumption and directly result in weight loss. However, growing literature suggests more complex effects on hepatic growth factor and cartilage and up-and downregulation of a variety of receptors and neurotransmitters involved throughout the growth system. These effects could plausibly result in initial growth Table 2 ). Different dashed lines identify children who had ADHD diagnostic codes only ("ADHD Dx Without Stimulant Use"), stimulant orders only ("Stimulant Use Without ADHD Dx"), or both ("ADHD Dx With Stimulant Use"), compared with children without a history of ADHD or stimulant use (solid line). The predicted BMI values were from the fixed portion of the model using observed population means for gender, race/ ethnicity, and medical assistance. , and community type (borough, census tract). b STIMAgeGx indicates age of first stimulant medication order; G1 through G4 represent the 4 quartiles of age of first stimulant order compared with children not taking stimulants as the reference group. retardation, possible tolerance to growth inhibition over time, and then rebound growth. 2, 4, [24] [25] [26] [27] [28] Temporary growth retardation related to stimulant therapy may partly explain altered growth trajectories among children with ADHD, but alternate hypotheses may also implicate the pathophysiology of ADHD. 25 Although direct evidence is generally lacking, 4 several hypotheses have been considered. A dysmaturity hypothesis suggested that among some children with ADHD, development and rate of growth may be delayed in early life, but this may lessen with age. 25 This hypothesis was explained by the fact that height, but not weight, retardation was observed in young children with ADHD but not among older children at 4-year followup, and no association was found between height deficits and stimulant use. 25 Our findings do not support this hypothesis; children with an ADHD diagnosis and without any stimulant orders had higher BMIs. Psychological hypotheses have been offered, including deficient inhibitory control, poor executive functions, and inability to monitor eating behaviors. 2, 10, [29] [30] [31] [32] Regarding neurobiological correlates, dysfunction of fronto-striatal dopaminergic pathways has been implicated in ADHD, 30 as well as in obesity 33 ; whereas stimulant therapy may function in the short-term to minimize this dysfunction, its longterm effect may diminish.
Our findings suggest that children with ADHD are at increased risk for obesity. Consistent with current guidelines, clinicians should assess and evaluate BMI at least annually and implement the indicated intervention to prevent obesity. 34 It should be noted that behavioral therapy, specifically parent training, can be effective 35 for ADHD management and has no known BMI rebound effect. Future research should examine how obesity prevention interventions may be best tailored and delivered to Table 3 ). Different dashed lines identify children whose first stimulant order was before age 7.1, 7.1 to 9.3, 9.3 to 12.3, and 12.3 to 18.9 years, compared with children without a history of ADHD or stimulant use (solid line). The predicted BMI values were from the fixed portion of the model using observed population means for gender, race/ethnicity, and medical assistance. , race/ethnicity (separate terms for black, Hispanic, and other), race/ethnicity*age, race/ethnicity*age 2 , medical assistance, medical assistance*age, medical assistance*age 2 , medical assistance*age 3 , and community type (borough, census tract). b STIMDurGx indicates duration of stimulant medication orders with duration based on method of allocating more than 1 prescription on the same day to subsequent months; G1 through G4 represent the 4 quartiles of stimulant duration compared with children not taking stimulants as the reference group. families with children who have ADHD and comorbidities.
This study had several strengths, including study of children who represent the general population in the region, longitudinal and detailed health information, measured height and weight, a large sample size, the inclusion of boys and girls, and a rigorous approach to data analysis. Among limitations, the study had limited diversity by race/ ethnicity, so findings may not be generalizable to more diverse populations. BMI data were not complete for all children at all ages and no information was available on medication adherence. Although the EHR data were extensive, we cannot exclude the possibility that children received diagnosis or treatment of ADHD by outside providers. EHR data also do not allow perfect ascertainment of diagnosis and treatment indications, but 91.6% of stimulant orders had an associated ICD-9-CM code for ADHD, and most of the remaining stimulant orders were for children who had a previous encounter with an ICD-9-CM code for ADHD.
CONCLUSIONS
The findings suggest that stimulant use, rather than ADHD itself, is most strongly associated with growth trajectories in childhood, early BMI rebound, and later obesity. Stimulants appear to slow the rate of BMI growth in early to midchildhood and then to accelerate growth rates in later childhood, generally after discontinuation of the medication. The findings have relevance to concerns raised about growth rate and its potential adverse long-term consequences. Our findings should motivate greater attention to the possibility that longer-term stimulant use plays a role in the development of obesity in children. 
